

IN THE DRAWINGS:

In accordance with 37 C.F.R. § 1.121, Applicants hereby submit a copy of originally filed Figure 2 with proposed amendments in red for approval by the Examiner. Applicants request approval of the proposed drawing changes.

IN THE CLAIMS:

Please cancel claims 26-32 and 36-42 without prejudice or disclaimer to the subject matter recited therein.

Please replace claims 24 and 25 as follows:

24. (Amended) A method for the treatment of multiple sclerosis comprising administering an effective amount of naked DNA capable of expressing beta-interferon to a patient in need of such treatment.

25. (Amended) A pharmaceutical composition for the treatment of multiple sclerosis comprising an effective amount of naked DNA capable of expressing beta-interferon and a pharmaceutically acceptable carrier therefor.

REMARKS

Entry of the foregoing, reexamination and further and favorable reconsideration of the subject application in light of the following remarks, pursuant to and consistent with 37 C.F.R. § 1.112, are respectfully requested.